Moreover, Palomo-Garo et al. have investigated the alterations in the endocannabinoid signaling system in the basal ganglia during the progression of the disease in a transgenic PD mouse model expressing the G2019S mutation of leucine-rich repeat kinase 2 (LRRK2), focusing on the CB2 receptor, and have also analyzed the effects of cannabinoids that selectively target the CB2 receptor in this model [62]. Here, LRRK2 is linked to Parkinson disease.